Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cells and Viruses
2.2. Preparation of the PCV2 Virus Cultures
2.3. Vaccination and Challenge of Pigs
2.4. Antibody Responses to Vaccination
2.5. Virus Neutralization Assay
2.6. Quantification of Viral Loads by qPCR
2.7. Pathological Evaluation
2.8. Statistical Analysis
3. Results
3.1. Booster Vaccination Induces Strong Antibody Responses
3.2. Vaccination Induces Strong Virus Neutralizing Antibody Responses
3.3. Vaccination Significantly Reduces Challenge Viral Replication
3.4. Clinical Observations
3.5. Vaccination Prevents the Development of Lesions
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ellis, J.; Hassard, L.; Clark, E.; Harding, J.; Allan, G.; Willson, P.; Strokappe, J.; Martin, K.; McNeilly, F.; Meehan, B.; et al. Isolation of circovirus from lesions of pigs with postweaning multisystemic wasting syndrome. Can. Vet. J. 1998, 39, 44–51. [Google Scholar] [PubMed]
- Harding, J.C. The clinical expression and emergence of porcine circovirus 2. Vet. Microbiol. 2004, 98, 131–135. [Google Scholar] [CrossRef] [PubMed]
- Alarcon, P.; Rushton, J.; Wieland, B. Cost of post-weaning multi-systemic wasting syndrome and porcine circovirus type-2 subclinical infection in England—an economic disease model. Prev. Vet. Med. 2013, 110, 88–102. [Google Scholar] [CrossRef] [PubMed]
- Ramamoorthy, S.; Meng, X.J. Porcine circoviruses: A minuscule yet mammoth paradox. Anim. Health Res. Rev. 2009, 10, 1–20. [Google Scholar] [CrossRef] [PubMed]
- Segales, J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev. Vaccines 2015, 14, 473–487. [Google Scholar] [CrossRef] [PubMed]
- Afghah, Z.; Webb, B.; Meng, X.J.; Ramamoorthy, S. Ten years of PCV2 vaccines and vaccination: Is eradication a possibility? Vet. Microbiol. 2017, 206, 21–28. [Google Scholar] [CrossRef] [PubMed]
- Constans, M.; Ssemadaali, M.; Kolyvushko, O.; Ramamoorthy, S. Antigenic Determinants of Possible Vaccine Escape by Porcine Circovirus Subtype 2b Viruses. Bioinform. Bio. Insights 2015, 9, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Firth, C.; Charleston, M.A.; Duffy, S.; Shapiro, B.; Holmes, E.C. Insights into the evolutionary history of an emerging livestock pathogen: Porcine circovirus 2. J. Virol. 2009, 83, 12813–12821. [Google Scholar] [CrossRef]
- Huang, L.; Wang, Y.; Wei, Y.; Chen, D.; Liu, D.; Du, W.; Xia, D.; Wu, H.; Feng, L.; Liu, C. Capsid proteins from PCV2a genotype confer greater protection against a PCV2b strain than those from PCV2b genotype in pigs: Evidence for PCV2b strains becoming more predominant than PCV2a strains from 2000 to 2010s. Appl. Microbiol. Biotechnol. 2016, 100, 5933–5943. [Google Scholar] [CrossRef]
- Rose, N.; Andraud, M.; Bigault, L.; Jestin, A.; Grasland, B. A commercial PCV2a-based vaccine significantly reduces PCV2b transmission in experimental conditions. Vaccine 2016, 34, 3738–3745. [Google Scholar] [CrossRef]
- Guo, L.; Fu, Y.; Wang, Y.; Lu, Y.; Wei, Y.; Tang, Q.; Fan, P.; Liu, J.; Zhang, L.; Zhang, F.; et al. A porcine circovirus type 2 (PCV2) mutant with 234 amino acids in capsid protein showed more virulence in vivo, compared with classical PCV2a/b strain. PLoS ONE 2012, 7, e41463. [Google Scholar] [CrossRef] [PubMed]
- Xiao, C.T.; Halbur, P.G.; Opriessnig, T. Complete genome sequence of a novel porcine circovirus type 2b variant present in cases of vaccine failures in the United States. J. Virol. 2012, 86, 12469. [Google Scholar] [CrossRef] [PubMed]
- Han, K.; Seo, H.W.; Oh, Y.; Park, C.; Kang, I.; Jang, H.; Chae, C. Efficacy of a piglet-specific commercial inactivated vaccine against Porcine circovirus type 2 in clinical field trials. Canadian J. Vet. Res. 2013, 77, 237–240. [Google Scholar]
- Madson, D.M.; Patterson, A.R.; Ramamoorthy, S.; Pal, N.; Meng, X.J.; Opriessnig, T. Effect of porcine circovirus type 2 (PCV2) vaccination of the dam on PCV2 replication in utero. Clin. Vaccine Immunol. 2009, 16, 830–834. [Google Scholar] [CrossRef] [PubMed]
- Ssemadaali, M.A.; Ilha, M.; Ramamoorthy, S. Genetic diversity of porcine circovirus type 2 and implications for detection and control. Res. Vet. Sci. 2015, 103, 179–186. [Google Scholar] [CrossRef]
- Xiao, C.T.; Halbur, P.G.; Opriessnig, T. Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d. J. Gen. Virol. 2015, 96, 1830–1841. [Google Scholar] [CrossRef]
- Park, K.H.; Oh, T.; Yang, S.; Cho, H.; Kang, I.; Chae, C. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge. Vet. Microbiol. 2019, 231, 87–92. [Google Scholar] [CrossRef]
- Opriessnig, T.; Xiao, C.T.; Halbur, P.G.; Gerber, P.F.; Matzinger, S.R.; Meng, X.J. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naive pigs under experimental conditions. Vaccine 2017, 35, 248–254. [Google Scholar] [CrossRef]
- Fenaux, M.; Opriessnig, T.; Halbur, P.G.; Elvinger, F.; Meng, X.J. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J. Virol. 2004, 78, 6297–6303. [Google Scholar] [CrossRef]
- Gagnon, C.A.; Music, N.; Fontaine, G.; Tremblay, D.; Harel, J. Emergence of a new type of porcine circovirus in swine (PCV): A type 1 and type 2 PCV recombinant. Vet. Microbiol. 2010, 144, 18–23. [Google Scholar] [CrossRef]
- Fenaux, M.; Opriessnig, T.; Halbur, P.G.; Meng, X.J. Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs. J. Virol. 2003, 77, 11232–11243. [Google Scholar] [CrossRef] [PubMed]
- Opriessnig, T.; Ramamoorthy, S.; Madson, D.M.; Patterson, A.R.; Pal, N.; Carman, S.; Meng, X.J.; Halbur, P.G. Differences in virulence among porcine circovirus type 2 isolates are unrelated to cluster type 2a or 2b and prior infection provides heterologous protection. J. Gen. Virol. 2008, 89, 2482–2491. [Google Scholar] [CrossRef] [PubMed]
- Ramamoorthy, S.; Huang, F.F.; Huang, Y.W.; Meng, X.J. Interferon-mediated enhancement of in vitro replication of porcine circovirus type 2 is influenced by an interferon-stimulated response element in the PCV2 genome. Virus Res. 2009, 145, 236–243. [Google Scholar] [CrossRef] [PubMed]
- Carr, J. Pig Stockmanship; 5M Enterprises: Sheffield, UK, 1998; p. 64. [Google Scholar]
- Matzinger, S.R.; Opriessnig, T.; Xiao, C.T.; Catanzaro, N.; Beach, N.M.; Slade, D.E.; Nitzel, G.P.; Meng, X.J. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs. Virology 2016, 498, 82–93. [Google Scholar] [CrossRef] [PubMed]
- Meerts, P.; Misinzo, G.; Lefebvre, D.; Nielsen, J.; Botner, A.; Kristensen, C.S.; Nauwynck, H.J. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Vet. Res. 2006, 2, 6. [Google Scholar] [CrossRef] [PubMed]
- Opriessnig, T.; Yu, S.; Gallup, J.M.; Evans, R.B.; Fenaux, M.; Pallares, F.; Thacker, E.L.; Brockus, C.W.; Ackermann, M.R.; Thomas, P.; et al. Effect of vaccination with selective bacterins on conventional pigs infected with type 2 porcine circovirus. Vet. Pathol. 2003, 40, 521–529. [Google Scholar] [CrossRef] [PubMed]
- Jeong, J.; Park, C.; Choi, K.; Chae, C. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b. Vet. Microbiol. 2015, 177, 43–52. [Google Scholar] [CrossRef]
- Opriessnig, T.; Gerber, P.F.; Xiao, C.T.; Halbur, P.G.; Matzinger, S.R.; Meng, X.J. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2. Vaccine 2014, 32, 4342–4348. [Google Scholar] [CrossRef]
- Seo, H.W.; Oh, Y.; Han, K.; Park, C.; Chae, C. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge. BMC Vet. Res. 2012, 8, 194. [Google Scholar] [CrossRef]
- Fraile, L.; Grau-Roma, L.; Sarasola, P.; Sinovas, N.; Nofrarias, M.; Lopez-Jimenez, R.; Lopez-Soria, S.; Sibila, M.; Segales, J. Inactivated PCV2 one shot vaccine applied in 3-week-old piglets: Improvement of production parameters and interaction with maternally derived immunity. Vaccine 2012, 30, 1986–1992. [Google Scholar] [CrossRef]
- Opriessnig, T.; Patterson, A.R.; Elsener, J.; Meng, X.J.; Halbur, P.G. Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2. Clin. Vaccine Immunol. 2008, 15, 397–401. [Google Scholar] [CrossRef] [PubMed]
- Tassis, P.D.; Tsakmakidis, I.; Papatsiros, V.G.; Koulialis, D.; Nell, T.; Brellou, G.; Tzika, E.D. A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs. BMC Vet. Res. 2017, 13, 91. [Google Scholar] [CrossRef] [PubMed]
- Opriessnig, T.; Patterson, A.R.; Madson, D.M.; Pal, N.; Halbur, P.G. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination. Vaccine 2009, 27, 1002–1007. [Google Scholar] [CrossRef] [PubMed]
- Martelli, P.; Ferrari, L.; Morganti, M.; De Angelis, E.; Bonilauri, P.; Guazzetti, S.; Caleffi, A.; Borghetti, P. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet. Microbiol. 2011, 149, 339–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seo, H.W.; Han, K.; Oh, Y.; Kang, I.; Park, C.; Chae, C. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines on PCV2 shedding in semen from experimentally infected boars. Vet. Microbiol. 2013, 164, 145–149. [Google Scholar] [CrossRef]
Group | Overall Lesion Score % (No. of Positive Animals/Total Animals) | Overall IHC Score & (No. of Positive Animals/Total Animals) | Total Mean Pathology Score (No. of Positive Animals/Total Animals) # |
---|---|---|---|
PBS | 3.43 ± 8.22 (2/7) | 9.14 ± 3.98 (7/7) | 27.44 ± 13.04 (7/7) |
Vaccinated | 0 (0/7) | 0 a (0/7) | 0 a (0/7) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kolyvushko, O.; Rakibuzzaman, A.; Pillatzki, A.; Webb, B.; Ramamoorthy, S. Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d. Vet. Sci. 2019, 6, 61. https://doi.org/10.3390/vetsci6030061
Kolyvushko O, Rakibuzzaman A, Pillatzki A, Webb B, Ramamoorthy S. Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d. Veterinary Sciences. 2019; 6(3):61. https://doi.org/10.3390/vetsci6030061
Chicago/Turabian StyleKolyvushko, Oleksandr, AGM Rakibuzzaman, Angela Pillatzki, Brett Webb, and Sheela Ramamoorthy. 2019. "Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d" Veterinary Sciences 6, no. 3: 61. https://doi.org/10.3390/vetsci6030061